keyword
MENU ▼
Read by QxMD icon Read
search

Phase 3 cancer

keyword
https://www.readbyqxmd.com/read/29232580/design-and-synthesis-of-novel-quinacrine-1-3-thiazinan-4-one-hybrids-for-their-anti-breast-cancer-activity
#1
V Raja Solomon, Sheetal Pundir, Hoang-Thanh Le, Hoyun Lee
In an attempt to develop effective and safe anticancer agents, we designed, synthesized and examined 23 novel quinacrine (QC) derivatives by combining the 9-aminoacridine scaffold and the [1,3]thiazinan-4-ones group. Most of these hybrids showed strong anticancer activities, among which 3-(3-(6-chloro-2-methoxyacridin-9-ylamino)propyl)-2-(thiophen-2-yl)-1,3-thiazinan-4-one (25; VR151) effectively killed many different cancer cell types, including eight breast cancer cell lines with different genetic background, two prostate cancer and two lung cancer cell lines...
December 9, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29231728/protective-effect-of-mulberry-morus-alba-l-extract-against-benzo-a-pyrene-induced-skin-damage-through-inhibition-of-aryl-hydrocarbon-receptor-signaling
#2
Hyunju Woo, JungA Lee, Deokhoon Park, Eunsun Jung
Benzo[a]pyrene (B[a]P), a type of polycyclic aromatic hydrocarbon, is present in the atmosphere surrounding our environment. Although B[a]P is a procarcinogen, enzymatically metabolized benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) could intercalate into DNA to form bulky BPDE-DNA adducts as an ultimate carcinogenic product in human keratinocytes. The aim of this study was to evaluate the protective effect of mulberry extract, purified from the fruit of Morus Alba L., on B[a]P-induced cytotoxicity in human keratinocytes and its mechanisms of action...
December 12, 2017: Journal of Agricultural and Food Chemistry
https://www.readbyqxmd.com/read/29230663/advantages-with-prophylactic-peg-rhg-csf-versus-rhg-csf-in-breast-cancer-patients-receiving-multiple-cycles-of-myelosuppressive-chemotherapy-an-open-label-randomized-multicenter-phase-iii-study
#3
Jie Xie, Jun Cao, Jing-Fen Wang, Bai-Hong Zhang, Xiao-Hua Zeng, Hong Zheng, Yang Zhang, Li Cai, Yu-Dong Wu, Qiang Yao, Xiao-Chun Zhao, Wei-Dong Mao, Ai-Mei Jiang, Shao-Shui Chen, Shun-E Yang, Shu-Sen Wang, Jian-Hong Wang, Yue-Yin Pan, Bi-Yong Ren, Yan-Ju Chen, Li-Zhi Ouyang, Kai-Jian Lei, Jing-Hua Gao, Wen-He Huang, Zhan Huang, Tao Shou, Yan-Ling He, Jing Cheng, Yang Sun, Wei-Ming Li, Shu-de Cui, Xin Wang, Zhi-Guo Rao, Hu Ma, Wei Liu, Xue-Yong Wu, Wei-Xi Shen, Fei-Lin Cao, Ze-Min Xiao, Biao Wu, Shu-Yan Tian, Dong Meng, Peng Shen, Bi-Yun Wang, Zhonghua Wang, Jian Zhang, Leiping Wang, Xi-Chun Hu
BACKGROUND: PEG-rhG-CSF reduces neutropenia and improves chemotherapy safety. In China's registration trial (CFDA: 2006L01305), we assessed its efficacy and safety against rhG-CSF, and prospectively explored its value over multiple cycles of chemotherapy. METHODS: In this open-label, randomized, multicenter phase 3 study, breast cancer patients (n = 569) were randomized to receive PEG-rhG-CSF 100 µg/kg, PEG-rhG-CSF 6 mg, or rhG-CSF 5 µg/kg/d after chemotherapy...
December 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29229325/prospective-phase-2-trial-of-permanent-seed-implantation-prostate-brachytherapy-for-intermediate-risk-localized-prostate-cancer-efficacy-toxicity-and-quality-of-life-outcomes
#4
Steven J Frank, Thomas J Pugh, Pierre Blanchard, Usama Mahmood, William J Graber, Rajat J Kudchadker, John W Davis, Jeri Kim, Haesun Choi, Patricia Troncoso, Deborah A Kuban, Seungtaek Choi, Sean McGuire, Karen E Hoffman, Hsiang-Chun Chen, Xuemei Wang, David A Swanson
PURPOSE: To report the efficacy, physician-reported toxicity, and patient-reported outcomes of men with intermediate-risk prostate cancer after brachytherapy in a prospective phase 2 trial. METHODS AND MATERIALS: This prospective phase 2 trial involved 300 patients with previously untreated prostate cancer treated from 2006 through 2013. Eligible patients had ≤cT2b (T3 excluded according to magnetic resonance imaging), Gleason score (GS) 6 with prostate-specific antigen (PSA) level 10-15 ng/mL, or GS 7 with PSA <10 ng/mL, and were treated with prostate brachytherapy (without hormonal therapy)...
October 12, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29228969/race-associated-biological-differences-among-luminal-a-and-basal-like-breast-cancers-in-the-carolina-breast-cancer-study
#5
Humberto Parada, Xuezheng Sun, Jodie M Fleming, ClarLynda R Williams-DeVane, Erin L Kirk, Linnea T Olsson, Charles M Perou, Andrew F Olshan, Melissa A Troester
BACKGROUND: We examined racial differences in the expression of eight genes and their associations with risk of recurrence among 478 white and 495 black women who participated in the Carolina Breast Cancer Study Phase 3. METHODS: Breast tumor samples were analyzed for PAM50 subtype and for eight genes previously found to be differentially expressed by race and associated with breast cancer survival: ACOX2, MUC1, FAM177A1, GSTT2, PSPH, PSPHL, SQLE, and TYMS. The expression of these genes according to race was assessed using linear regression and each gene was evaluated in association with recurrence using Cox regression...
December 11, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29228771/curcumin-derivative-epigenetically-reactivates-nrf2-antioxidative-stress-signaling-in-mouse-prostate-cancer-tramp-c1-cells
#6
Wenji Li, Zheng-Yuan Su, Yue Guo, Chengyue Zhang, RenYi Wu, Linbo Gao, Xi Zheng, Zhi-Yun Du, Kun Zhang, Ah-Ng Kong
The carcinogenesis of prostate cancer (PCa) in TRAMP model is highly correlated with hypermethylation in the promoter region of Nrf2 and the accompanying reduced transcription of Nrf2 and its regulated detoxifying genes. We aimed to investigate the effects of (3E,5E)-3,5-Bis(3,4,5-trimethoxybenzylidene) -tetrahydrothiopyran-4-one (F10) and (3E,5E)-3,5-Bis(3,4,5-trimethoxybenzylidene) -tetrahydropyran-4-one (E10), two synthetic curcumin derivatives, on restoring Nrf2 activity in TRAMP C1 cells. HepG2-C8 cells transfected with an antioxidant-response element (ARE)-luciferase vector were treated with F10, E10, curcumin and sulforaphane (SFN) to compare their effects on Nrf2-ARE pathways...
December 11, 2017: Chemical Research in Toxicology
https://www.readbyqxmd.com/read/29228761/targeting-tumor-associated-carbohydrate-antigens-a-phase-i-study-of-a-carbohydrate-mimetic-peptide-vaccine-in-stage-iv-breast-cancer-subjects
#7
Laura F Hutchins, Issam Makhoul, Peter D Emanuel, Angela Pennisi, Eric R Siegel, Fariba Jousheghany, Xueyan Guo, Anastas D Pashov, Behjatolah Monzavi-Karbassi, Thomas Kieber-Emmons
Tumor-associated carbohydrate antigens (TACAs) support cell survival that could be interrupted by anti-TACA antibodies. Among TACAs that mediate cell survival signals are the neolactoseries antigen Lewis Y (LeY) and the ganglioside GD2. To induce sustained immunity against both LeY and GD2, we developed a carbohydrate mimicking peptide (CMP) as a surrogate pan-immunogen that mimics both. This CMP, referred to as P10s, is the N-terminal half of a peptide vaccine named P10s-PADRE, the C-terminal half of which (PADRE) is a Pan-T-cell epitope...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228678/high-expression-of-pdlim5-facilitates-cell-tumorigenesis-and-migration-by-maintaining-ampk-activation-in-prostate-cancer
#8
Xi Liu, Lu Chen, Hai Huang, Jian-Min Lv, Ming Chen, Fa-Jun Qu, Xiu-Wu Pan, Lin Li, Lei Yin, Xin-Gang Cui, Yi Gao, Dan-Feng Xu
PDZ and LIM domain 5 (PDLIM5) is a cytoskeleton-associated protein and has been shown to bind to a variety of proteins through its specific domain, thereby acting to regulate cell migration and tumor progression. Here, we found that PDLIM5 was abnormally upregulated in prostate cancer (PCa) tissues as compared with that in normal prostate tissue. ONCOMINE microarray data mining showed that PDLIM5 was closely correlated with the prognosis of PCa in terms of Gleason score, tumor metastasis and biochemical recurrence...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228659/prospective-randomized-phase-ii-study-of-folfiri-versus-folfox7-in-advanced-gastric-adenocarcinoma-a-chinese-western-cooperative-gastrointestinal-oncology-group-study
#9
Qiu Li, Feng Wen, Chengya Zhou, Meng Qiu, Jiyan Liu, Jing Chen, Cheng Yi, Zhiping Li, Deyun Luo, Feng Xu, Xiaohong Cai, Feng Bi
Until now, no standard chemotherapy has been widely accepted for advanced gastric cancer (GC). The current research aimed to compare folinic acid, fluorouracil with irinotecan (mFOLFIRI) or with oxaliplatin (mFOLFOX7) as first-line treatments in patients with locally advanced GC in an open, randomized, phase II study. Previously untreated metastatic or recurrent GC patients with measurable disease received mFOLFIRI (arm A) or mFOLFOX7 (arm B) every 2 weeks. The defined second-line treatment was mFOLFOX7 for arm A and mFOLFIRI for arm B...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228656/increased-pdgfr-beta-and-vegfr-2-protein-levels-are-associated-with-resistance-to-platinum-based-chemotherapy-and-adverse-outcome-of-ovarian-cancer-patients
#10
Stefanie Avril, Yasemin Dincer, Katharina Malinowsky, Claudia Wolff, Sibylle Gündisch, Alexander Hapfelmeier, Melanie Boxberg, Holger Bronger, Karl-Friedrich Becker, Barbara Schmalfeldt
Despite frequent initial response rates of epithelial ovarian cancer to platinum-based chemotherapy the majority of patients develop drug resistance. Our aim was to evaluate differential expression of signaling-pathway proteins in platinum-sensitive versus platinum-resistant primary epithelial ovarian cancer specimens to identify predictive biomarkers for treatment response. 192 patients were studied comprising of independent training (n = 89) and validation (n = 103) cohorts. Full-length proteins were extracted from paraffin-embedded samples including multiple regions per tumor to account for intratumoral heterogeneity...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228640/comparison-of-primary-endpoints-between-publications-registries-and-protocols-of-phase-iii-cancer-clinical-trials
#11
Fei Liang, Xinmei Guo, Sheng Zhang, Hongxi Xue, Qiang Chen, Xichun Hu
Background: Decisions by leading journals to require trial registration and to make protocols of phase III randomized clinical trials (RCTs) publicly accessible were landmark events in clinical trial reporting. Materials and Methods: We identified phase III cancer RCTs published between 2013 and 2015 in New England Journal of Medicine (NEJM), The Lancet, The lancet Oncology, JAMA and Journal of Clinical Oncology (JCO). Results: We identified 345 reports of phase III RCTs of which 217 (62...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228425/up-regulation-of-linc00346-inhibits-proliferation-of-non-small-cell-lung-cancer-cells-through-mediating-jak-stat3-signaling-pathway
#12
F Wang, J-G Chen, L-L Wang, Z-Z Yan, S-P Chen, X-G Wang
OBJECTIVE: To investigate the expression levels of LINCRNA00346 in tissues and cells in patients with non-small cell lung cancer (NSCLC) and its biological function. PATIENTS AND METHODS: The relative expression levels of LINC 00346 in 70 cases of tissues and cells in NSCLC patients were detected via quantitative reverse transcription polymerase chain reaction (qRT-PCR). The specific interference sequences of LINC 00346 were designed and the transfection efficiency after 48 h was detected...
November 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29228091/a-randomized-phase-ii-study-evaluating-different-maintenance-schedules-of-nab-paclitaxel-in-the-first-line-treatment-of-metastatic-breast-cancer-final-results-of-the-ibcsg-42-12-big-2-12-snap-trial
#13
A Gennari, Z Sun, U Hasler-Strub, M Colleoni, M J Kennedy, R Von Moos, J Cortés, M J Vidal, B Hennessy, J Walshe, K Amillano Parraga, K Ribi, J Bernhard, S Murillo Morales, O Pagani, A Barbeaux, S Borstnar, M Rabaglio-Poretti, R Maibach, M M Regan, G Jerusalem
Background: The phase II SNAP trial was designed to evaluate the efficacy of alternative chemotherapy schedules for prolonged administration in HER2-negative metastatic breast cancer (MBC), after a short induction at conventional doses. Methods: Between April 2013 and August 2015, 258 women untreated with chemotherapy for MBC were randomly assigned to receive three different maintenance chemotherapy schedules after three cycles of identical induction chemotherapy: Arm A, nab-Paclitaxel 150 mg/m2 days 1,15 Q28; Arm B, nab-Paclitaxel 100 mg/m2 days 1,8,15 Q28; Arm C, nab-Paclitaxel 75 mg/m2 days 1,8,15,22 Q28...
December 8, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29228087/analysis-of-angiogenesis-biomarkers-for-ramucirumab-efficacy-in-patients-with-metastatic-colorectal-cancer-from-raise-a-global-randomized-double-blind-phase-iii-study
#14
J Tabernero, R R Hozak, T Yoshino, A L Cohn, R Obermannova, G Bodoky, R Garcia-Carbonero, T-E Ciuleanu, D C Portnoy, J Prausová, K Muro, R W Siegel, R J Konrad, H Ouyang, S A Melemed, D Ferry, F Nasroulah, E Van Cutsem
Background: The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo+FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. To identify patients who benefit the most from VEGFR-2 blockade, the RAISE trial design included a prospective and comprehensive biomarker program that assessed the association of biomarkers with ramucirumab efficacy outcomes...
December 7, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29227281/targeting-mcl-1-enhances-dna-replication-stress-sensitivity-to-cancer-therapy
#15
Guo Chen, Andrew T Magis, Ke Xu, Dongkyoo Park, David S Yu, Taofeek K Owonikoko, Gabriel L Sica, Sarah W Satola, Suresh S Ramalingam, Walter J Curran, Paul W Doetsch, Xingming Deng
DNA double-strand breaks (DSBs) are mainly repaired either by homologous recombination (HR) or by nonhomologous end-joining (NHEJ) pathways. Here, we showed that myeloid cell leukemia sequence 1 (Mcl-1) acts as a functional switch in selecting between HR and NHEJ pathways. Mcl-1 was cell cycle-regulated during HR, with its expression peaking in S/G2 phase. While endogenous Mcl-1 depletion reduced HR and enhanced NHEJ, Mcl-1 overexpression resulted in a net increase in HR over NHEJ. Mcl-1 directly interacted with the dimeric Ku protein complex via its Bcl-2 homology 1 and 3 (BH1 and BH3) domains, which are required for Mcl-1 to inhibit Ku-mediated NHEJ...
December 11, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29226849/assessment-of-global-and-local-region-based-bilateral-mammographic-feature-asymmetry-to-predict-short-term-breast-cancer-risk
#16
Yane Li, Ming Fan, Hu Cheng, Peng Zhang, Bin Zheng, Lihua Li
This study aims to develop and test a new imaging marker-based short-term breast cancer risk prediction model. An age-matched dataset of 566 screening mammography cases was used. All "prior" images acquired in the two screening series were negative, while in the "current" screening images, 283 cases were positive for cancer and 283 cases remained negative. For each case, two bilateral cranio-caudal view mammograms acquired from the "prior" negative screenings were selected and processed by a computer-aided image processing scheme, which segmented the entire breast area into 9 strip-based local regions, extracted the element regions using difference of Gaussian filters, and computed both global- and local-based bilateral asymmetrical image features...
December 11, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/29225263/a-phase-i-ii-study-for-dose-finding-and-to-investigate-the-safety-pharmacokinetics-and-preliminary-efficacy-of-nk012-an-sn-38-incorporating-macromolecular-polymeric-micelle-in-patients-with-multiple-myeloma
#17
Masaki Ri, Kenshi Suzuki, Shinsuke Iida, Kiyohiko Hatake, Takaaki Chou, Masafumi Taniwaki, Noriko Watanabe, Tetsuji Tsukamoto
Objective Multiple myeloma (MM) is the second most common hematological cancer. An attempt to treat MM using a topoisomerase I inhibitor was made based on our previous non-clinical studies suggesting the usefulness of an SN-38 derivative. Our aim was to conduct a phase I/II study of NK012, a micelle-forming SN-38 conjugate, in patients with relapsed/refractory multiple myeloma (RRMM). Methods NK012 was administered at doses of 12-24 mg/m2 and the safety, pharmacokinetics and preliminary efficacy were evaluated...
December 8, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29225132/ginsenoside-rh4-induces-apoptosis-and-autophagic-cell-death-through-activation-of-the-ros-jnk-p53-pathway-in-colorectal-cancer-cells
#18
Qian Wu, Jianjun Deng, Daidi Fan, Zhiguang Duan, Chenhui Zhu, Rongzhan Fu, Shanshan Wang
The use of ginsenosides in cancer therapy has been intensively investigated. The ginsenoside Rh4 (Rh4), a rare saponin obtained from Panax notoginseng, dissolves in water more readily than total saponins, making this compound easier to use in anti-cancer pharmaceutics. Here, we investigated the antiproliferative activity and mechanisms of Rh4 in colorectal cancer, both in vivo and in vitro. A colorectal cancer xenograft model showed that Rh4 significantly inhibited tumor growth with few side effects. CCK-8 assays, flow cytometric analysis, Western blotting and immunohistochemistry revealed that Rh4 effectively suppressed colorectal cancer cell proliferation via inducing G0/G1 phase arrest, caspase-dependent apoptosis and autophagic cell death but was not significantly cytotoxic to normal colon epithelial cells...
December 7, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29224898/clinical-outcome-of-patients-with-advanced-biliary-tract-cancer-in-a-dedicated-phase-i-unit
#19
R Sundar, A Custodio, A Petruckevich, M Chénard-Poirier, M Ameratunga, D Collins, J Lim, S B Kaye, N Tunariu, U Banerji, J de Bono, J Lopez
AIMS: Advanced biliary tract carcinomas (ABC) are malignancies with limited effective therapies for advanced disease. There is little published evidence of outcomes of ABC patients participating in phase I clinical trials. MATERIALS AND METHODS: Patient characteristics, treatment details and outcomes of ABC patients treated at a dedicated phase I unit were captured and analysed from case and trial records. RESULTS: In total, 123 ABC patients were included in the study, of which 48 patients participated in 41 different phase I trials; 75 (61%) did not participate due to rapid disease progression or patient choice...
December 7, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29224367/effect-of-ruxolitinib-therapy-on-the-quality-of-life-of-japanese-patients-with-myelofibrosis
#20
Kenji Oritani, Kohshi Ohishi, Shinichiro Okamoto, Keita Kirito, Norio Komatsu, Tetsuzo Tauchi, Hiroshi Handa, Shigeki Saito, Katsuto Takenaka, Kazuya Shimoda, Hikaru Okada, Taro Amagasaki, Shiho Wakase, Kojiro Shimozuma, Koichi Akashi
OBJECTIVES: Myelofibrosis (MF) is associated with a significant symptom burden that severely impacts patient quality of life (QOL). Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QOL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy. We evaluated the effect of ruxolitinib on symptoms and QOL in Japanese patients with MF. METHODS: We conducted a pooled analysis of studies A2202 (NCT01392443) and AJP01 (NCT02087059) of ruxolitinib in Japanese patients with MF (N = 81)...
December 9, 2017: Current Medical Research and Opinion
keyword
keyword
17437
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"